CRISPR/Cas9, a new approach to successful knockdown of ABCB1/P-glycoprotein and reversal of chemosensitivity in human epithelial ovarian cancer cell line by Norouzi-Barough, Leyla et al.
  
 
 
 
 
 
  
 
  
 
Iranian Journal of Basic Medical Sciences 
 
ijbms.mums.ac.ir 
CRISPR/Cas9, a new approach to successful knockdown of 
ABCB1/P-glycoprotein and reversal of chemosensitivity in 
human epithelial ovarian cancer cell line 
 
Leyla Norouzi-Barough 1, Mohammadreza Sarookhani 2*, Rasoul Salehi 3, Mohammadreza 
Sharifi 3, Sahar Moghbelinejad 4 
 
1 Department of Molecular Medicine, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran 
2 Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran 
3 Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 
4 Department of Biochemistry and Genetic, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran 
 
A R T I C L E  I N F O  A B S T R A C T 
 
Article type: 
Original article 
 
  
Objective(s): Multidrug resistance (MDR) is a major obstacle in the successful chemotherapy of ovarian 
cancer. Inhibition of P-glycoprotein (P-gp), a member of ATP-binding cassette (ABC) transporters, is a 
well-known strategy to overcome MDR in cancer. The aim of this study was to investigate the efficiency 
and ability of CRISPR/Cas9 genome editing technology to knockdown ABCB1 gene expression in 
adriamycin resistant (A2780/ADR) ovarian cancer cell line and evaluate the sensitivity changes to 
doxorubicin. 
Materials and Methods: Three single-guide RNAs (sgRNAs) targeting the fourth and fifth exons of human 
ABCB1 gene were designed in this study. Expression level of ABCB1 was detected using quantitative real time 
PCR (qRT-PCR) after co-transfection of all three sgRNAs into A2780/ADR cell line and subsequent antibiotic 
selection. Drug sensitivity to doxorubicin was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay.  
Results: The results showed that CRISPR/Cas9 system could significantly reduce the expression of P-
gp. The dramatic decline in ABCB1 gene expression was associated with increased sensitivity of cells 
transfected with sgRNAs to doxorubicin.  
Conclusion: Based on the results of this study, it is concluded that the CRISPR-based systems, used in 
the present study, effectively down-regulated the target gene and acted as an ideal and cost-effective 
tool for gene editing of A2780/ADR cell line resulting in restoration of nonmalignant phenotype. 
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Introduction 
Epithelial ovarian cancer is the sixth most common 
cancer and most lethal gynecological malignancy among 
women (1, 2). Due to the location of the ovaries within 
the pelvis, ovarian cancer does not represent specific 
symptoms in the early stages. Therefore, two thirds of 
the patients are diagnosed at the advanced stages and 
5-year survival rate is estimated to be less than 25% 
(3–5). Surgery and chemotherapy are recommended as 
initial treatment and taxane therapy with a platinum 
analog is the backbone of chemotherapy (6, 7). Despite 
these strategies, recurrence often occurs within 2 years. 
These relapsing tumors often exhibit chemo-resistance 
towards several anti-cancer agents with various structures 
and mechanisms of action (3, 8). MDR in cancer is generally 
the result of increased expression of membrane efflux 
proteins which belong to the ATP-binding cassette (ABC) 
 
transporters superfamily. Consequently, cancer cells actively 
transfer a wide variety of pharmaceutical compounds, including 
chemotherapeutic agents out of the cells, resulting in 
reduced intracellular drug accumulation in resistant cells 
(9). Classical multidrug resistance to chemotherapeutic 
agents is attributed to the overexpression of ABCB1 
gene (known as P-glycoprotein (P-gp) or MDR1) (10). It 
has been documented that overexpression of P-gp is the 
key factor for reduced chemo-sensitivity in a wide range 
of tumors, including ovarian cancer (11, 12). Couple of 
studies have indicated that several signal transduction 
pathways are involved in dysregulation of ABCB1 gene. 
According to this, it seems that targeting ABCB1, as a 
downstream object in multiple pathways, is the ideal 
choice to restore drug sensitivity in MDR cancer cells 
(9,13). Over the past decade, a revolutionary technology 
named genome editing has been developed that provides 
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